Mentara Therapeutics
Clinical-stage neuroscience biotech developing MTA-304 for levodopa-induced dyskinesia in Parkinson's
About
Mentara Therapeutics is a Melbourne-based, clinical-stage neuroscience company developing therapies for neuropsychiatric and neurodegenerative disorders. Its lead asset MTA-304 (formerly EM-221) is a second-generation PDE10A inhibitor for levodopa-induced dyskinesia (LID) in Parkinson's disease; it has completed three Phase 1 studies in 86 participants and the company is targeting a Phase 2 trial in the first half of 2027. Mentara launched in October 2026 with an undisclosed round led by SPRIM Global Investments, with former EuMentis Therapeutics shareholders rolling over into the new company. CEO is Frank D. Stonebanks and CMO is Dr. Randall D. Marshall. MTA-304 is investigational and not approved.
- Website
- mentaratherapeutics.com
- Location
- Melbourne, Australia
- Added via
- web
- Ownership
- unclaimed